Beam Therapeutics (BEAM) Depreciation & Amortization (CF) (2020 - 2026)
Beam Therapeutics (BEAM) posted quarterly Depreciation & Amortization (CF) of $5.6 million for Q1 2026, up 1.39% year-over-year from $5.5 million in Q1 2025, and down 1.11% quarter-over-quarter from $5.7 million in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 1.39% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $22.4 million (up 1.58% YoY), while the FY2025 annual figure was $22.3 million, up 1.68% from the prior year.
- Depreciation & Amortization (CF) retreated to $5.6 million in Q1 2026 per BEAM's latest filing, from $5.7 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $5.7 million in Q4 2025 and bottomed at $3.3 million in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $4.9 million across 5 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 136.91% — and 2025, when it slipped 0.68%.
- Beam Therapeutics' Depreciation & Amortization (CF) stood at $3.9 million in 2022, then soared by 35.95% to $5.4 million in 2023, then climbed by 1.51% to $5.4 million in 2024, then increased by 4.13% to $5.7 million in 2025, then decreased by 1.11% to $5.6 million in 2026.
- Business Quant data shows BEAM's Depreciation & Amortization (CF) at $5.6 million in Q1 2026, $5.7 million in Q4 2025, and $5.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | 5.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.41 Mn |
| Mar 31, 2026 | 5.61 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.56 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Mar 31, 2025 | 5.53 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 5.58 Mn |
| Mar 31, 2024 | 5.43 Mn |
| Dec 31, 2023 | 5.36 Mn |
| Sep 30, 2023 | 5.19 Mn |
| Jun 30, 2023 | 4.82 Mn |
| Mar 31, 2023 | 4.65 Mn |
| Dec 31, 2022 | 3.94 Mn |
| Sep 30, 2022 | 3.47 Mn |
| Jun 30, 2022 | 3.42 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 1.75 Mn |